Market closed
Recursion Pharmaceuticals/$RXRX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Recursion Pharmaceuticals
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Ticker
$RXRX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
500
Website
RXRX Metrics
BasicAdvanced
$2.2B
Market cap
-
P/E ratio
-$1.54
EPS
0.80
Beta
-
Dividend rate
Price and volume
Market cap
$2.2B
Beta
0.8
52-week high
$15.74
52-week low
$5.22
Average daily volume
4.7M
Financial strength
Current ratio
4.355
Quick ratio
3.948
Long term debt to equity
14.14
Total debt to equity
17.276
Interest coverage (TTM)
-398.03%
Management effectiveness
Return on assets (TTM)
-36.40%
Return on equity (TTM)
-78.49%
Valuation
Price to revenue (TTM)
28.562
Price to book
4.13
Price to tangible book (TTM)
4.95
Price to free cash flow (TTM)
-5.547
Growth
Revenue change (TTM)
37.64%
Earnings per share change (TTM)
4.30%
3-year revenue growth (CAGR)
84.75%
3-year earnings per share growth (CAGR)
-2.64%
What the Analysts think about RXRX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Recursion Pharmaceuticals stock.
RXRX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RXRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RXRX News
AllArticlesVideos
Recursion and Exscientia Shareholders Approve the Proposed Combination
GlobeNewsWire·11 hours ago
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden
GlobeNewsWire·1 day ago
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Recursion Pharmaceuticals stock?
Recursion Pharmaceuticals (RXRX) has a market cap of $2.2B as of November 14, 2024.
What is the P/E ratio for Recursion Pharmaceuticals stock?
The price to earnings (P/E) ratio for Recursion Pharmaceuticals (RXRX) stock is 0 as of November 14, 2024.
Does Recursion Pharmaceuticals stock pay dividends?
No, Recursion Pharmaceuticals (RXRX) stock does not pay dividends to its shareholders as of November 14, 2024.
When is the next Recursion Pharmaceuticals dividend payment date?
Recursion Pharmaceuticals (RXRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Recursion Pharmaceuticals?
Recursion Pharmaceuticals (RXRX) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.